
Learn why single-cell technologies are vital for Endometriosis research by watching our webinar
Endometriosis is a debilitating disease that affects 10% of women and girls of reproductive age. There is no cure, no certain cause and no non-invasive method of diagnosing the disease, leading to a reduced quality of life for the patients and a significant socio-economic burden. Join us on our webinar on why single-cell technologies are vital for endometriosis research.
Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of this disease requires a novel research approach by single-cell analysis. Therefore, Prof. Dr. med. Müller started collaborating with Scailyte AG, the specialist in single-cell analysis. In a joint project, they strive to develop a non-invasive diagnosis method, and potentially a prognostic method to reduce the suffering of endometriosis patients. Prof. Mueller is a renowned gynaecologist and gynaecological oncologist, and managing director of the Women’s Health Clinic at the University Hospital of Bern (Inselspital). He is the founding member and current president of the working group for Endoscopic Gynecology.
Join this webinar with Prof. Mueller, in cooperation with Scailyte, to learn more about “Why single-cell technologies are vital for Endometriosis research.”
Watch the webinar here: https://youtu.be/XPmhGRy-1AY
About Scailyte
Recent News
Meet Scailyte at BioTechX
Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.
Recent News
Scailyte closes Series A funding with a CHF 6 million investment
Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of
Recent News
VACANCY: Internship in Women’s Health R&D
The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en
Recent News
Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t
Recent News
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow
Recent News
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better
Recent News
VACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
VACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
Meet Scailyte at BioTechX
Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.
Scailyte closes Series A funding with a CHF 6 million investment
Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of
Recent News
VACANCY: Internship in Women’s Health R&D
The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en
Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t
Recent News
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better
Recent News
VACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel
VACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel